- c.€3.4 million by issuing shares with warrants
- Subscription price: €1.37 for one share with
warrants
- 1 warrant gives entitlement to 1 share to be issued at a
price of €3
- Exercise period: 3 years
- Visibility extended to end 2025
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA
PME), a new generation biotech company dedicated to the
discovery and development of innovative therapies based on the
world’s only natural recombinant apoA-I, announces the success of a
capital increase with cancellation of preferential subscription
rights for the benefit of a category of persons for an amount of
close to €3.4 million through the issue of a maximum number of
2,472,000 new shares, each with a warrant, at a subscription price
of €1.37 per share with warrants.
Each new share will be issued with a warrant, and each warrant
will entitle its holder to subscribe for 1 new share to be issued
at a price of €3.
Objective of the fundraising
The objective of this fundraising is to strengthen the Company's
cash position as part of its development in sepsis and in the
United States, following the successful pre-IND meeting with the
FDA. The Company's financial visibility has now been extended to
end 2025, with no further drawdown of the equity-linked financing
facility.
Terms and conditions of the issue
Further to the decisions taken by the decisions by the Board of
Directors on June 19 and 21, the Chief Executive Officer has today
recorded full subscription of the following shares of 2,472,000
ordinary shares with a par value of €0.05, each carrying a warrant
to subscribe for new ordinary shares. The shares with warrants
issued at a price of €1.37, representing a nominal capital increase
of €123,600 and a issue premium of €3,263,040.
The subscription price of each share with warrant corresponds to
the weighted average of the 10 trading days preceding June 19,
2024, less a 10% discount and plus the estimated value of the
warrant of 0.18 euro.
Upon creation of the share with warrants, the warrants will be
detached from the shares.
This issue represents approximately 7.62% of the share capital
as of the date of the issue decision.
The new shares carry dividend rights, are assimilated to
existing shares and carry the same rights. They are subject to all
the provisions of the Company's bylaws and are admitted to trading
on Euronext on the same trading line as the existing shares.
Each warrant will entitle its holder to subscribe for one new
share at a price of €3.
The warrants are exercisable between November 30, 2024, and June
19, 2027. They are transferable and negotiable but are not be
subject of an application for admission to trading on Euronext.
Exercise of all the warrants could give rise to the issue of up
to 2,472,000 new ordinary shares, representing additional gross
proceeds of €7,416,000.
This operation involves a capital increase with cancellation of
preferential subscription rights for the benefit of a category of
persons, decided by the Board of Directors on June 19 and 21, 2024,
acting on the basis of the delegation granted by the twentieth
resolution of the Company's Combined General Meeting of June 27,
2023.
Delivery settlement
Settlement and delivery is scheduled for Wednesday, July 3,
2024.
Issue proceeds
The gross proceeds from the shares with warrants issue amount to
€3,386,640, representing a net amount of €3,356,640, after
deduction of issue-related costs.
Exercise of all the warrants would generate additional gross
proceeds of €7,416,000.
Shareholder structure
The number of shares likely to be issued represents around 7.62%
of the number of shares outstanding before issue and 7.08% after
issue of the shares with warrants.
By way of illustration, a shareholder who held a number of
shares representing 1% of ABIONYX's share capital before the
planned issue would represent 0.93% of the share capital after the
shares with warrant issue (in the event of full subscription to the
capital increase) and 0.87% of the share capital (in the event of
exercise of all the warrants).
Shareholders* before and after capital increase in % of
capital
Shareholders
12/31/2023*
Post-issuance of shares with
warrants
Post exercise of
warrants
Nb shares and
% Capital and
Nb shares and
% Capital and
Nb shares and
% Capital
and
Voting rights
Voting rights
Voting rights
Voting rights
Voting rights
Voting rights
Total top management
6,148,342
18.94%
6,148,342
17.60%
6,148,342
16.44%
Emmanuel Huynh
4,348,882
13.40%
4,348,882
12.45%
4,348,882
11.63%
Cyrille Tupin
1,592,214
4.91%
1,592,214
4.56%
1,592,214
4.26%
Christian Chavy
207,246
0.64%
207,246
0.59%
207,246
0.55%
Total financial shareholders
6,622,787
20.40%
9,094,787
26.04%
11,566,787
30.92%
Orsay 53 (represented by Mr. Jean-Gérard
Galvez)
2,331,000
6.67%
4,662,000
12.46%
Sadok Belmokhtar
1,859,098
5.73%
1,859,098
5.32%
1,859,098
4.97%
Luc Demarre
1,846,457
5.69%
1,987,457
5.69%
2,128,457
5.69%
BPI Participations (FR)
1,630,451
5.02%
1,630,451
4.67%
1,630,451
4.36%
Jean-Louis Dasseux
1,286,781
3.96%
1,286,781
3.68%
1,286,781
3.44%
Free float
19,422,744
59.84%
19,422,744
55.60%
19,422,744
51.93%
Treasury shares
265,139
0.82%
265,139
0.76%
265,139
0.71%
TOTAL
32,459,012
100.00%
34,931,012
100.00%
37,403,012
100.00%
*On the basis of information brought to the Company's attention,
in particular for bearer shareholders via declarations of crossing
thresholds (legal and statutory).
Some of the individual shareholders listed in the table above
hold all or part of their interests through holding companies that
they manage and control.
Absence of prospectus
In accordance with the provisions of Article 211-3 of the
General Regulations of the Autorité des Marchés Financiers (AMF),
the issue will not give rise to a prospectus subject to AMF
approval.
Risk factors
Risk factors are described in the Universal Registration
Document 2023 (chapter 3) filed with the AMF under number D.24-0385
on April 30, 2024, and available on the Company's website:
www.abionyx.com and that of the AMF: www.amf-france.org.
Number of shares making up the share capital
Following the issue of shares with warrants, the share capital
now stands at €1,746,550.60. It is divided into 34,931,012 ordinary
shares with a par value of €0.05, representing 34,931,012
theoretical voting rights.
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on
developing innovative medicines for diseases where there is no
effective or existing treatment, even the rarest ones. The company
expedites the development of novel therapeutics through an
extensive expertise in lipid science and a differentiated
apoA-I-based technology platform. ABIONYX Pharma is committed to
radically improving treatment outcomes in Sepsis and critical
care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240701444059/en/
NewCap Investor relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
過去 株価チャート
から 6 2024 まで 7 2024
Abionyx Pharma (EU:ABNX)
過去 株価チャート
から 7 2023 まで 7 2024
